Ted Cohen

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6267607/publications.pdf

Version: 2024-02-01

200 papers	10,903 citations	41344 49 h-index	40979 93 g-index
221 all docs	221 docs citations	221 times ranked	12679 citing authors

#	Article	IF	Citations
1	Transmission Dynamics and Control of Severe Acute Respiratory Syndrome. Science, 2003, 300, 1966-1970.	12.6	1,281
2	Negative Controls. Epidemiology, 2010, 21, 383-388.	2.7	923
3	Mycobacterium tuberculosis mutation rate estimates from different lineages predict substantial differences in the emergence of drug-resistant tuberculosis. Nature Genetics, 2013, 45, 784-790.	21.4	405
4	Effects of smoking and solid-fuel use on COPD, lung cancer, and tuberculosis in China: a time-based, multiple risk factor, modelling study. Lancet, The, 2008, 372, 1473-1483.	13.7	261
5	Genomic analysis of globally diverse Mycobacterium tuberculosis strains provides insights into the emergence and spread of multidrug resistance. Nature Genetics, 2017, 49, 395-402.	21.4	258
6	Incidence of multidrug-resistant tuberculosis disease in children: systematic review and global estimates. Lancet, The, 2014, 383, 1572-1579.	13.7	256
7	Modeling epidemics of multidrug-resistant M. tuberculosis of heterogeneous fitness. Nature Medicine, 2004, 10, 1117-1121.	30.7	249
8	Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models. The Lancet Global Health, 2014, 2, e23-e34.	6.3	188
9	Origin and Proliferation of Multiple-Drug Resistance in Bacterial Pathogens. Microbiology and Molecular Biology Reviews, 2015, 79, 101-116.	6.6	183
10	Antiviral Resistance and the Control of Pandemic Influenza. PLoS Medicine, 2007, 4, e15.	8.4	182
11	Mixed-Strain Mycobacterium tuberculosis Infections and the Implications for Tuberculosis Treatment and Control. Clinical Microbiology Reviews, 2012, 25, 708-719.	13.6	172
12	Population Health Impact and Cost-Effectiveness of Tuberculosis Diagnosis with Xpert MTB/RIF: A Dynamic Simulation and Economic Evaluation. PLoS Medicine, 2012, 9, e1001347.	8.4	168
13	The risk of tuberculosis in children after close exposure: a systematic review and individual-participant meta-analysis. Lancet, The, 2020, 395, 973-984.	13.7	160
14	The effect of drug resistance on the fitness of Mycobacterium tuberculosis. Lancet Infectious Diseases, The, 2003, 3, 13-21.	9.1	151
15	The transmission of Mycobacterium tuberculosis in high burden settings. Lancet Infectious Diseases, The, 2016, 16, 227-238.	9.1	149
16	Strengthening the Reporting of Molecular Epidemiology for Infectious Diseases (STROME-ID): an extension of the STROBE statement. Lancet Infectious Diseases, The, 2014, 14, 341-352.	9.1	145
17	Feasibility of achieving the 2025 WHO global tuberculosis targets in South Africa, China, and India: a combined analysis of 11 mathematical models. The Lancet Global Health, 2016, 4, e806-e815.	6.3	138
18	Genomic diversity in autopsy samples reveals within-host dissemination of HIV-associated Mycobacterium tuberculosis. Nature Medicine, 2016, 22, 1470-1474.	30.7	133

#	Article	IF	Citations
19	No coexistence for free: Neutral null models for multistrain pathogens. Epidemics, 2009, 1, 2-13.	3.0	130
20	Drivers of Tuberculosis Transmission. Journal of Infectious Diseases, 2017, 216, S644-S653.	4.0	123
21	Beyond the SNP Threshold: Identifying Outbreak Clusters Using Inferred Transmissions. Molecular Biology and Evolution, 2019, 36, 587-603.	8.9	121
22	Exogenous re-infection and the dynamics of tuberculosis epidemics: local effects in a network model of transmission. Journal of the Royal Society Interface, 2007, 4, 523-531.	3.4	112
23	Beneficial and perverse effects of isoniazid preventive therapy for latent tuberculosis infection in HIV-tuberculosis coinfected populations. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 7042-7047.	7.1	107
24	Diabetes mellitus and tuberculosis in countries with high tuberculosis burdens: individual risks and social determinants. International Journal of Epidemiology, 2011, 40, 417-428.	1.9	105
25	The Prevalence and Drug Sensitivity of Tuberculosis among Patients Dying in Hospital in KwaZulu-Natal, South Africa: A Postmortem Study. PLoS Medicine, 2010, 7, e1000296.	8.4	98
26	Seasonality of Antibioticâ€ResistantStreptococcus pneumoniaeThat Causes Acute Otitis Media: A Clue for an Antibioticâ€Restriction Policy?. Journal of Infectious Diseases, 2008, 197, 1094-1102.	4.0	93
27	Data for action: collection and use of local data to end tuberculosis. Lancet, The, 2015, 386, 2324-2333.	13.7	89
28	Internal migration and transmission dynamics of tuberculosis in Shanghai, China: an epidemiological, spatial, genomic analysis. Lancet Infectious Diseases, The, 2018, 18, 788-795.	9.1	85
29	What is the mechanism for persistent coexistence of drug-susceptible and drug-resistant strains of Streptococcus pneumoniae ?. Journal of the Royal Society Interface, 2010, 7, 905-919.	3.4	83
30	Development of Extensively Drug-resistant Tuberculosis during Multidrug-resistant Tuberculosis Treatment. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 426-432.	5.6	82
31	The path of least resistance: aggressive or moderate treatment?. Proceedings of the Royal Society B: Biological Sciences, 2014, 281, 20140566.	2.6	79
32	Progression from latent infection to active disease in dynamic tuberculosis transmission models: a systematic review of the validity of modelling assumptions. Lancet Infectious Diseases, The, 2018, 18, e228-e238.	9.1	79
33	Quantifying the Burden and Trends of Isoniazid Resistant Tuberculosis, 1994â€“2009. PLoS ONE, 2011, 6, e22927.	2.5	78
34	Rapid Drug Susceptibility Testing of Drug-Resistant Mycobacterium tuberculosis Isolates Directly from Clinical Samples by Use of Amplicon Sequencing: a Proof-of-Concept Study. Journal of Clinical Microbiology, 2016, 54, 2058-2067.	3.9	76
35	Lifetime burden of disease due to incident tuberculosis: a global reappraisal including post-tuberculosis sequelae. The Lancet Global Health, 2021, 9, e1679-e1687.	6.3	74
36	Spontaneous Emergence of Multiple Drug Resistance in Tuberculosis before and during Therapy. PLoS ONE, 2011, 6, e18327.	2.5	71

#	Article	IF	Citations
37	Mixed-Strain Mycobacterium tuberculosis Infections among Patients Dying in a Hospital in KwaZulu-Natal, South Africa. Journal of Clinical Microbiology, 2011, 49, 385-388.	3.9	71
38	Cost-effectiveness and resource implications of aggressive action on tuberculosis in China, India, and South Africa: a combined analysis of nine models. The Lancet Global Health, 2016, 4, e816-e826.	6.3	69
39	Classic reaction kinetics can explain complex patterns of antibiotic action. Science Translational Medicine, 2015, 7, 287ra73.	12.4	67
40	Assessing spatial heterogeneity of multidrug-resistant tuberculosis in a high-burden country. European Respiratory Journal, 2013, 42, 1291-1301.	6.7	64
41	The Impact of Antiretroviral Therapy on Mortality in HIV Positive People during Tuberculosis Treatment: A Systematic Review and Meta-Analysis. PLoS ONE, 2014, 9, e112017.	2.5	63
42	Identifying Hotspots of Multidrug-Resistant Tuberculosis Transmission Using Spatial and Molecular Genetic Data. Journal of Infectious Diseases, 2016, 213, 287-294.	4.0	62
43	Epidemiologic Inference From the Distribution of Tuberculosis Cases in Households in Lima, Peru. Journal of Infectious Diseases, 2011, 203, 1582-1589.	4.0	58
44	Prospects for Tuberculosis Elimination in the United States: Results of a Transmission Dynamic Model. American Journal of Epidemiology, 2018, 187, 2011-2020.	3.4	58
45	Data needs for evidence-based decisions: a tuberculosis modeler's â€˜wish listâ€™ [Review article]. International Journal of Tuberculosis and Lung Disease, 2013, 17, 866-877.	1.2	57
46	Smear positivity in paediatric and adult tuberculosis: systematic review and meta-analysis. BMC Infectious Diseases, 2016, 16, 282.	2.9	57
47	Assessment of the patient, health system, and population effects of Xpert MTB/RIF and alternative diagnostics for tuberculosis in Tanzania: an integrated modelling approach. The Lancet Global Health, 2014, 2, e581-e591.	6.3	55
48	Evaluating strategies for control of tuberculosis in prisons and prevention of spillover into communities: An observational and modeling study from Brazil. PLoS Medicine, 2019, 16, e1002737.	8.4	55
49	Incidence and prevalence of tuberculosis in incarcerated populations: a systematic review and meta-analysis. Lancet Public Health, The, 2021, 6, e300-e308.	10.0	54
50	Isoniazid Resistance and the Future of Drug-Resistant Tuberculosis. Microbial Drug Resistance, 2004, 10, 280-285.	2.0	52
51	The impact of new tuberculosis diagnostics on transmission: why context matters. Bulletin of the World Health Organization, 2012, 90, 739-747.	3.3	51
52	The Effect of HIV-Related Immunosuppression on the Risk of Tuberculosis Transmission to Household Contacts. Clinical Infectious Diseases, 2014, 58, 765-774.	5.8	51
53	Post-tuberculosis mortality and morbidity: valuing the hidden epidemic. Lancet Respiratory Medicine,the, 2020, 8, 332-333.	10.7	50
54	Incident Tuberculosis among Recent US Immigrants and Exogenous Reinfection. Emerging Infectious Diseases, 2005, 11, 725-728.	4.3	49

#	Article	IF	Citations
55	The Impact of Changes in Diagnostic Testing Practices on Estimates of COVID-19 Transmission in the United States. American Journal of Epidemiology, 2021, 190, 1908-1917.	3.4	49
56	Challenges in Estimating the Total Burden of Drug-resistant Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 1302-1306.	5.6	47
57	Generalized Markov models of infectious disease spread: A novel framework for developing dynamic health policies. European Journal of Operational Research, 2011, 215, 679-687.	5.7	46
58	Within-Host Heterogeneity ofMycobacterium tuberculosisInfection Is Associated With Poor Early Treatment Response: A Prospective Cohort Study. Journal of Infectious Diseases, 2016, 213, 1796-1799.	4.0	45
59	How the Dynamics and Structure of Sexual Contact Networks Shape Pathogen Phylogenies. PLoS Computational Biology, 2013, 9, e1003105.	3.2	43
60	Outcomes among tuberculosis patients with isoniazid resistance in Georgia, 2007â€“2009. International Journal of Tuberculosis and Lung Disease, 2012, 16, 812-816.	1.2	42
61	Community-Wide Isoniazid Preventive Therapy Drives Drug-Resistant Tuberculosis: A Model-Based Analysis. Science Translational Medicine, 2013, 5, 180ra49.	12.4	42
62	Catastrophic costs potentially averted by tuberculosis control in India and South Africa: a modelling study. The Lancet Global Health, 2017, 5, e1123-e1132.	6.3	41
63	Spatially targeted screening to reduce tuberculosis transmission in high-incidence settings. Lancet Infectious Diseases, The, 2019, 19, e89-e95.	9.1	41
64	The Distribution of Fitness Costs of Resistance-Conferring Mutations Is a Key Determinant for the Future Burden of Drug-Resistant Tuberculosis: A Model-Based Analysis. Clinical Infectious Diseases, 2015, 61, S147-S154.	5.8	40
65	Modeling the effects of strain diversity and mechanisms of strain competition on the potential performance of new tuberculosis vaccines. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 16302-16307.	7.1	39
66	Age-Specific Risks of Tuberculosis Infection From Household and Community Exposures and Opportunities for Interventions in a High-Burden Setting. American Journal of Epidemiology, 2014, 180, 853-861.	3.4	39
67	Investigating spillover of multidrug-resistant tuberculosis from a prison: a spatial and molecular epidemiological analysis. BMC Medicine, 2018, 16, 122.	5.5	39
68	How competition governs whether moderate or aggressive treatment minimizes antibiotic resistance. ELife, 2015, 4, .	6.0	39
69	Transmissibility and potential for disease progression of drug resistantMycobacterium tuberculosis: prospective cohort study. BMJ: British Medical Journal, 2019, 367, l5894.	2.3	38
70	The escalating tuberculosis crisis in central and South American prisons. Lancet, The, 2021, 397, 1591-1596.	13.7	38
71	A modelling framework to support the selection and implementation of new tuberculosis diagnostic tools [State of the art series. Operational research. Number 8 in the series]. International Journal of Tuberculosis and Lung Disease, 2011, 15, 996-1004.	1.2	36
72	The potential impact of coinfection on antimicrobial chemotherapy and drug resistance. Trends in Microbiology, 2015, 23, 537-544.	7.7	36

#	Article	IF	Citations
73	The Impact of Realistic Age Structure in Simple Models of Tuberculosis Transmission. PLoS ONE, 2010, 5, e8479.	2.5	36
74	Mathematical models of the epidemiology and control of drug-resistant TB. Expert Review of Respiratory Medicine, 2009, 3, 67-79.	2.5	35
75	Identifying dynamic tuberculosis case-finding policies for HIV/TB coepidemics. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 9457-9462.	7.1	34
76	Isoniazid-resistant Tuberculosis in Children. Pediatric Infectious Disease Journal, 2013, 32, e217-e226.	2.0	34
77	Tuberculosis control interventions targeted to previously treated people in a high-incidence setting: a modelling study. The Lancet Global Health, 2018, 6, e426-e435.	6.3	34
78	Disparities in access to diagnosis and care in Blantyre, Malawi, identified through enhanced tuberculosis surveillance and spatial analysis. BMC Medicine, 2019, 17, 21.	5.5	34
79	High Rates of Potentially Infectious Tuberculosis and Multidrug-Resistant Tuberculosis (MDR-TB) among Hospital Inpatients in KwaZulu Natal, South Africa Indicate Risk of Nosocomial Transmission. PLoS ONE, 2014, 9, e90868.	2.5	34
80	On the spread and control of MDR-TB epidemics: An examination of trends in anti-tuberculosis drug resistance surveillance data. Drug Resistance Updates, 2014, 17, 105-123.	14.4	33
81	The potential effects of changing HIV treatment policy on tuberculosis outcomes in South Africa. Aids, 2014, 28, S25-S34.	2.2	33
82	High burden of prevalent tuberculosis among previously treated people in Southern Africa suggests potential for targeted control interventions. European Respiratory Journal, 2016, 48, 1227-1230.	6.7	33
83	Emergent heterogeneity in declining tuberculosis epidemics. Journal of Theoretical Biology, 2007, 247, 765-774.	1.7	30
84	Latent Coinfection and the Maintenance of Strain Diversity. Bulletin of Mathematical Biology, 2009, 71, 247-263.	1.9	30
85	Modeling the Dynamic Relationship Between HIV and the Risk of Drug-Resistant Tuberculosis. Science Translational Medicine, 2012, 4, 135ra67.	12.4	30
86	Bacillus Calmette-GuÃ©rin and Isoniazid Preventive Therapy Protect Contacts of Patients with Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 853-859.	5.6	30
87	HIV burden in men who have sex with men: a prospective cohort study 2007â€“2012. Scientific Reports, 2015, 5, 11205.	3.3	30
88	Personal digital assistants to collect tuberculosis bacteriology data in Peru reduce delays, errors, and workload, and are acceptable to users: cluster randomized controlled trial. International Journal of Infectious Diseases, 2009, 13, 410-418.	3.3	29
89	The dynamics of sexual contact networks: Effects on disease spread and control. Theoretical Population Biology, 2012, 81, 89-96.	1.1	29
90	Use of Cumulative Incidence of Novel Influenza A/H1N1 in Foreign Travelers to Estimate Lower Bounds on Cumulative Incidence in Mexico. PLoS ONE, 2009, 4, e6895.	2.5	29

#	Article	IF	Citations
91	Models to understand the population-level impact of mixed strain M. tuberculosis infections. Journal of Theoretical Biology, 2011, 280, 88-100.	1.7	28
92	Multidrug-resistant tuberculosis treatment failure detection depends on monitoring interval and microbiological method. European Respiratory Journal, 2016, 48, 1160-1170.	6.7	27
93	Yield, Efficiency, and Costs of Mass Screening Algorithms for Tuberculosis in Brazilian Prisons. Clinical Infectious Diseases, 2021, 72, 771-777.	5.8	27
94	Controversies and Unresolved Issues in Tuberculosis Prevention and Control: A Low-Burden-Country Perspective. Journal of Infectious Diseases, 2012, 205, S293-S300.	4.0	26
95	High risk and rapid appearance of multidrug resistance during tuberculosis treatment in Moldova. European Respiratory Journal, 2014, 43, 1132-1141.	6.7	26
96	Spatial measurement errors in the field of spatial epidemiology. International Journal of Health Geographics, 2016, 15, 21.	2.5	26
97	How can mathematical models advance tuberculosis control in high HIV prevalence settings?. International Journal of Tuberculosis and Lung Disease, 2014, 18, 509-514.	1.2	25
98	Fitness Costs of Drug Resistance Mutations in Multidrug-ResistantMycobacterium tuberculosis: A Household-Based Case-Control Study. Journal of Infectious Diseases, 2016, 213, 149-155.	4.0	25
99	Cigarette smoking among tuberculosis patients increases risk of transmission to child contacts. International Journal of Tuberculosis and Lung Disease, 2014, 18, 1285-1291.	1.2	24
100	Genomic variant-identification methods may alter Mycobacterium tuberculosis transmission inferences. Microbial Genomics, 2020, 6, .	2.0	24
101	Dynamic Health Policies for Controlling the Spread of Emerging Infections: Influenza as an Example. PLoS ONE, 2011, 6, e24043.	2.5	23
102	Modeling of Novel Diagnostic Strategies for Active Tuberculosis â€“ A Systematic Review: Current Practices and Recommendations. PLoS ONE, 2014, 9, e110558.	2.5	23
103	Multiple Introductions of Multidrug-Resistant Tuberculosis into Households, Lima, Peru. Emerging Infectious Diseases, 2011, 17, 969-975.	4.3	23
104	Global estimates of paediatric tuberculosis incidence in 2013â€“19: a mathematical modelling analysis. The Lancet Global Health, 2022, 10, e207-e215.	6.3	23
105	Drug Resistance Surveillance in Resource-Poor Settings: Current Methods and Considerations for TB, HIV, and Malaria. American Journal of Tropical Medicine and Hygiene, 2011, 84, 192-199.	1.4	20
106	Identifying multidrug resistant tuberculosis transmission hotspots using routinely collected data. Tuberculosis, 2012, 92, 273-279.	1.9	20
107	Effect of study design and setting on tuberculosis clustering estimates using Mycobacterial Interspersed Repetitive Units-Variable Number Tandem Repeats (MIRU-VNTR): a systematic review. BMJ Open, 2015, 5, e005636-e005636.	1.9	20
108	Priority-Setting for Novel Drug Regimens to Treat Tuberculosis: An Epidemiologic Model. PLoS Medicine, 2017, 14, e1002202.	8.4	20

#	Article	IF	Citations
109	Risk factors and timing of default from treatment for non-multidrug-resistant tuberculosis in Moldova. International Journal of Tuberculosis and Lung Disease, 2013, 17, 373-380.	1.2	19
110	How could preventive therapy affect the prevalence of drug resistance? Causes and consequences. Philosophical Transactions of the Royal Society B: Biological Sciences, 2015, 370, 20140306.	4.0	19
111	Magnitude and sources of bias in the detection of mixed strain M. tuberculosis infection. Journal of Theoretical Biology, 2015, 368, 67-73.	1.7	19
112	Assessing the utility of XpertÂ® MTB/RIF as a screening tool for patients admitted to medical wards in South Africa. Scientific Reports, 2016, 6, 19391.	3.3	19
113	Evaluation of Tuberculosis Treatment Response With Serial C-Reactive Protein Measurements. Open Forum Infectious Diseases, 2018, 5, ofy253.	0.9	19
114	Development of a Treatment-decision Algorithm for Human Immunodeficiency Virusâ€“uninfected Children Evaluated for Pulmonary Tuberculosis. Clinical Infectious Diseases, 2021, 73, e904-e912.	5.8	19
115	Are Survey-Based Estimates of the Burden of Drug Resistant TB Too Low? Insight from a Simulation Study. PLoS ONE, 2008, 3, e2363.	2.5	19
116	Negative Control Exposures in Epidemiologic Studies. Epidemiology, 2012, 23, 351-352.	2.7	18
117	Prospective evaluation of a complex public health intervention: lessons from an initial and follow-up cross-sectional survey of the tuberculosis strain typing service in England. BMC Public Health, 2014, 14, 1023.	2.9	18
118	A Multistrain Mathematical Model To Investigate the Role of Pyrazinamide in the Emergence of Extensively Drug-Resistant Tuberculosis. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	17
119	Where is tuberculosis transmission happening? Insights from the literature, new tools to study transmission and implications for the elimination of tuberculosis. Respirology, 2018, 23, 807-817.	2.3	17
120	Modelling the performance of isoniazid preventive therapy for reducing tuberculosis in HIV endemic settings: the effects of network structure. Journal of the Royal Society Interface, 2011, 8, 1510-1520.	3.4	16
121	Using Chemical Reaction Kinetics to Predict Optimal Antibiotic Treatment Strategies. PLoS Computational Biology, 2017, 13, e1005321.	3.2	16
122	Risk ratios for contagious outcomes. Journal of the Royal Society Interface, 2018, 15, 20170696.	3.4	16
123	Pan-tuberculosis regimens: an argument for. Lancet Respiratory Medicine,the, 2018, 6, 239-240.	10.7	16
124	Time Since Infection and Risks of Future Disease for Individuals with Mycobacterium tuberculosis Infection in the United States. Epidemiology, 2021, 32, 70-78.	2.7	16
125	Phylogeography and transmission of M. tuberculosis in Moldova: A prospective genomic analysis. PLoS Medicine, 2022, 19, e1003933.	8.4	16
126	Drivers and Trajectories of Resistance to New First-Line Drug Regimens for Tuberculosis. Open Forum Infectious Diseases, 2014, 1, ofu073.	0.9	15

#	Article	IF	Citations
127	Costâ€effectiveness of expanding the capacity of opioid agonist treatment in Ukraine: dynamic modeling analysis. Addiction, 2020, 115, 437-450.	3.3	15
128	Cost-effectiveness of post-treatment follow-up examinations and secondary prevention of tuberculosis in a high-incidence setting: a model-based analysis. The Lancet Global Health, 2020, 8, e1223-e1233.	6.3	15
129	Trends in C-Reactive Protein, D-Dimer, and Fibrinogen during Therapy for HIV-Associated Multidrug-Resistant Tuberculosis. American Journal of Tropical Medicine and Hygiene, 2018, 99, 1336-1341.	1.4	15
130	Test and treat in HIV: success could depend on rapid detection. Lancet, The, 2011, 378, 204-206.	13.7	14
131	ClassTR: Classifying Within-Host Heterogeneity Based on Tandem Repeats with Application to Mycobacterium tuberculosis Infections. PLoS Computational Biology, 2016, 12, e1004475.	3.2	14
132	Second line drug susceptibility testing to inform the treatment of rifampin-resistant tuberculosis: a quantitative perspective. International Journal of Infectious Diseases, 2017, 56, 185-189.	3.3	14
133	Impact of Effective Global Tuberculosis Control on Health and Economic Outcomes in the United States. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 1567-1575.	5.6	14
134	Multidrug Resistance Among New Tuberculosis Cases. Epidemiology, 2012, 23, 293-300.	2.7	13
135	Use of Spatial Information to Predict Multidrug Resistance in Tuberculosis Patients, Peru. Emerging Infectious Diseases, 2012, 18, 811-813.	4.3	13
136	Benefits of continuous isoniazid preventive therapy may outweigh resistance risks in a declining tuberculosis/HIV coepidemic. Aids, 2016, 30, 2715-2723.	2.2	13
137	Whole-genome sequencing of Mycobacterium tuberculosis for rapid diagnostics and beyond. Lancet Respiratory Medicine,the, 2016, 4, 6-8.	10.7	13
138	A Likelihood Approach for Real-Time Calibration of Stochastic Compartmental Epidemic Models. PLoS Computational Biology, 2017, 13, e1005257.	3.2	13
139	Comparative Modeling of Tuberculosis Epidemiology and Policy Outcomes in California. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 356-365.	5.6	13
140	Effectiveness of spatially targeted interventions for control of HIV, tuberculosis, leprosy and malaria: a systematic review. BMJ Open, 2021, 11, e044715.	1.9	13
141	Tuberculosis Among Participants in an Academic Global Health Medical Exchange Program. Journal of General Internal Medicine, 2011, 26, 841-845.	2.6	12
142	Effect of empirical treatment on outcomes of clinical trials of diagnostic assays for tuberculosis. Lancet Infectious Diseases, The, 2015, 15, 16-17.	9.1	12
143	Identifying costâ€effective dynamic policies to control epidemics. Statistics in Medicine, 2016, 35, 5189-5209.	1.6	12
144	The cost-effectiveness of alternative vaccination strategies for polyvalent meningococcal vaccines in Burkina Faso: A transmission dynamic modeling study. PLoS Medicine, 2018, 15, e1002495.	8.4	12

#	Article	IF	Citations
145	Changing Patterns of Spatial Clustering of Schistosomiasis in Southwest China between 1999â€“2001 and 2007â€“2008: Assessing Progress toward Eradication after the World Bank Loan Project. International Journal of Environmental Research and Public Health, 2014, 11, 701-712.	2.6	11
146	Polyclonal Pulmonary Tuberculosis Infections and Risk for Multidrug Resistance, Lima, Peru. Emerging Infectious Diseases, 2017, 23, 1887-1890.	4.3	11
147	Use of daily Internet search query data improves real-time projections of influenza epidemics. Journal of the Royal Society Interface, 2018, 15, 20180220.	3.4	11
148	Drug-target binding quantitatively predicts optimal antibiotic dose levels in quinolones. PLoS Computational Biology, 2020, 16, e1008106.	3.2	11
149	Linking Surveillance with Action against Drug-Resistant Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 399-401.	5.6	10
150	Risk factors for recurrent tuberculosis after successful treatment in a high burden setting: a cohort study. BMC Infectious Diseases, 2020, 20, 789.	2.9	10
151	The role of prisons in disseminating tuberculosis in Brazil: A genomic epidemiology study. The Lancet Regional Health Americas, 2022, 9, 100186.	2.6	10
152	MATHEMATICAL MODELS OF TUBERCULOSIS: ACCOMPLISHMENTS AND FUTURE CHALLENGES. , 2007, , .		9
153	Estimating the magnitude and direction of bias in tuberculosis drug resistance surveys conducted only in the public sector: a simulation study. BMC Public Health, 2010, 10, 355.	2.9	9
154	Evaluating the potential impact of enhancing HIV treatment and tuberculosis control programmes on the burden of tuberculosis. Journal of the Royal Society Interface, 2015, 12, 20150146.	3.4	9
155	Tradeoffs in Introduction Policies for the Anti-Tuberculosis Drug Bedaquiline: A Model-Based Analysis. PLoS Medicine, 2016, 13, e1002142.	8.4	9
156	Population implications of the use of bedaquiline in people with extensively drug-resistant tuberculosis: are fears of resistance justified?. Lancet Infectious Diseases, The, 2017, 17, e429-e433.	9.1	9
157	Towards better prediction of Mycobacterium tuberculosis lineages from MIRU-VNTR data. Infection, Genetics and Evolution, 2019, 72, 59-66.	2.3	9
158	Accurate quantification of uncertainty in epidemic parameter estimates and predictions using stochastic compartmental models. Statistical Methods in Medical Research, 2019, 28, 3591-3608.	1.5	9
159	Trends, Mechanisms, and Racial/Ethnic Differences of Tuberculosis Incidence in the US-Born Population Aged 50 Years or Older in the United States. Clinical Infectious Diseases, 2022, 74, 1594-1603.	5.8	9
160	Population Immunity to Pre-Omicron and Omicron Severe Acute Respiratory Syndrome Coronavirus 2 Variants in US States and Counties Through 1 December 2021. Clinical Infectious Diseases, 2023, 76, e350-e359.	5.8	9
161	Protective effects of household-based TB interventions are robust to neighbourhood-level variation in exposure risk in Lima, Peru: a model-based analysis. International Journal of Epidemiology, 2018, 47, 185-192.	1.9	8
162	Tracking and predicting U.S. influenza activity with a real-time surveillance network. PLoS Computational Biology, 2020, 16, e1008180.	3.2	8

#	Article	IF	Citations
163	Bayesian Estimation of Mixture Models with Prespecified Elements to Compare Drug Resistance in Treatment-NaÃ¯ve and Experienced Tuberculosis Cases. PLoS Computational Biology, 2013, 9, e1002973.	3.2	7
164	Adaptive Policies to Balance Health Benefits and Economic Costs of Physical Distancing Interventions during the COVID-19 Pandemic. Medical Decision Making, 2021, 41, 386-392.	2.4	7
165	High-resolution estimates of tuberculosis incidence among non-U.S.-born persons residing in the United States, 2000â€“2016. Epidemics, 2020, 33, 100419.	3.0	6
166	Adaptive guidelines for the treatment of gonorrhea to increase the effective life span of antibiotics among men who have sex with men in the United States: A mathematical modeling study. PLoS Medicine, 2020, 17, e1003077.	8.4	6
167	Use of Lot Quality Assurance Sampling to Ascertain Levels of Drug Resistant Tuberculosis in Western Kenya. PLoS ONE, 2016, 11, e0154142.	2.5	6
168	Neighbourhood prevalence-to-notification ratios for adult bacteriologically-confirmed tuberculosis reveals hotspots of underdiagnosis in Blantyre, Malawi. PLoS ONE, 2022, 17, e0268749.	2.5	6
169	Planning for the invisible: projecting resources needed to identify and treat all patients with MDR-TB [Editorial]. International Journal of Tuberculosis and Lung Disease, 2013, 17, 427-428.	1.2	5
170	The burden of tuberculosis disease in childrenâ€“Authors' reply. Lancet, The, 2014, 384, 1343-1344.	13.7	5
171	Eliminating tuberculosis in low-burden countries. International Journal of Tuberculosis and Lung Disease, 2018, 22, 3-3.	1.2	5
172	Protective impacts of household-based tuberculosis contact tracing are robust across endemic incidence levels and community contact patterns. PLoS Computational Biology, 2021, 17, e1008713.	3.2	5
173	Evolution and emergence of multidrug-resistant Mycobacterium tuberculosis in Chisinau, Moldova. Microbial Genomics, 2021, 7, .	2.0	5
174	A Cluster-based Method to Quantify Individual Heterogeneity in Tuberculosis Transmission. Epidemiology, 2022, 33, 217-227.	2.7	5
175	A tale of two settings: the role of the Beijing genotype in the epidemiology of multidrug-resistant tuberculosis. European Respiratory Journal, 2014, 43, 632-635.	6.7	4
176	Cost-Effectiveness of Alternative Uses of Polyvalent Meningococcal Vaccines in Niger: An Agent-Based Transmission Modeling Study. Medical Decision Making, 2019, 39, 553-567.	2.4	4
177	Ongoing challenges to understanding multidrug- and rifampicin-resistant tuberculosis in children versus adults. European Respiratory Journal, 2021, 57, 2002504.	6.7	4
178	The positive externalities of migrant-based TB control strategy in a Chinese urban population with internal migration: a transmission-dynamic modeling study. BMC Medicine, 2021, 19, 95.	5.5	4
179	Evaluation of 6-Month Versus Continuous Isoniazid Preventive Therapy for Mycobacterium tuberculosis in Adults Living With HIV/AIDS in Malawi. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 85, 643-650.	2.1	4
180	Evaluation of the Tuberculosis Strain Typing Service (TB-STS) in England. Lancet, The, 2013, 382, S73.	13.7	3

#	Article	IF	Citations
181	Response to Comment on â€œCommunity-Wide Isoniazid Preventive Therapy Drives Drug-Resistant Tuberculosis: A Model-Based Analysisâ€• Science Translational Medicine, 2013, 5, 204lr4.	12.4	2
182	Evidence sources on the natural history of latent tuberculosis infection. Lancet Infectious Diseases, The, 2018, 18, 834-835.	9.1	2
183	Assessing Local Risk of Rifampicin-Resistant Tuberculosis in KwaZulu-Natal, South Africa Using Lot Quality Assurance Sampling. PLoS ONE, 2016, 11, e0153143.	2.5	2
184	The Health and Economic Benefits of Tests That Predict Future Progression to Tuberculosis Disease. Epidemiology, 2022, 33, 75-83.	2.7	2
185	vCOMBAT: a novel tool to create and visualize a computational model of bacterial antibiotic target-binding. BMC Bioinformatics, 2022, 23, 22.	2.6	2
186	Bayesian methods for fitting mixture models that characterize branching tree processes: An application to development of resistant TB strains. Statistics in Medicine, 2011, 30, 2708-2720.	1.6	1
187	Antimicrobial Resistance Risks of Cholera Prophylaxis for United Nations Peacekeepers. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	1
188	Transmission Modeling with Regression Adjustment for Analyzing Household-based Studies of Infectious Disease. Epidemiology, 2020, 31, 238-247.	2.7	1
189	Children as sentinels of tuberculosis transmission: disease mapping of programmatic data. BMC Medicine, 2020, 18, 234.	5.5	1
190	Evaluating spatially adaptive guidelines for the treatment of gonorrhea to reduce the incidence of gonococcal infection and increase the effective lifespan of antibiotics. PLoS Computational Biology, 2022, 18, e1009842.	3.2	1
191	Predicting resistance to fluoroquinolones among patients with rifampicin-resistant tuberculosis using machine learning methods. , 2022, 1, e0000059.		1
192	Does Current Drug Resistance Surveillance Provide Useful Information in Tuberculosis?. American Journal of Respiratory and Critical Care Medicine, 2009, 179, 82-83.	5.6	0
193	Re: Supporting health systems for tuberculosis through research. Tuberculosis, 2012, 92, 290.	1.9	0
194	The contributions of Steve Lawn to the science, advocacy and policy of HIV-associated TB. International Journal of Tuberculosis and Lung Disease, 2016, 20, 1563-1564.	1.2	0
195	Reply to Chen et al. Journal of Infectious Diseases, 2016, 214, 1287-1288.	4.0	0
196	Spatially targeted digital chest radiography to reduce tuberculosis in high-burden settings: A study of adaptive decision making. Epidemics, 2022, 38, 100540.	3.0	0
197	Title is missing!. , 2020, 17, e1003077.		0
198	Title is missing!. , 2020, 17, e1003077.		0

#	Article	IF	Citations
199	Title is missing!. , 2020, 17, e1003077.		0
200	Title is missing!. , 2020, 17, e1003077.		0